LIST OF CONTRIBUTORS

Najah Abi-Gerges, AnaBios Corporation, San Diego, CA, USA

Michael D. Aleo, Investigative Toxicology, Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA

Daniel J. Antoine, MRC Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, The Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Michael Bachelor, MatTek Corporation, Ashland, MA, USA

Amanda F. Baker, Arizona Health Sciences Center, University of Arizona, Tucson, AZ, USA

Scott A. Barros, Investigative Toxicology, Alnylam Pharmaceuticals Inc., Cambridge, MA, USA

Kaïdre Bendjama, Transgene, Illkirch-Graffenstaden, France

Eric A.G. Blomme, AbbVie, Pharmaceutical Research & Development, North Chicago, IL, USA

Richard J. Brennan, Preclinical Safety, Sanofi SA, Waltham, MA, USA

Karrie A. Brenneman, Toxicologic Pathology, Drug Safety Research and Development, Pfizer Inc., Andover, MA, USA

Peter M. Burch, Investigative Pathology, Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA

Deborah A. Burt, Biomarker Development and Translation, Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA

Neal C. Burton, iThera Medical, GmbH, Munich, Germany

Nicholas Buss, Biologics Safety Assessment, MedImmune, Gaithersburg, MD, USA

Paul Butler, Global Safety Pharmacology, Drug Safety Research and Development, Pfizer Inc., La Jolla, CA, USA

Keri E. Cannon, Toxicology, Halozyme Therapeutics, Inc., San Diego, CA, USA

Minjun Chen, Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration (NCTR/FDA), Jefferson, AZ, USA

Yafei Chen, Mechanistic & Investigative Toxicology, Discovery Sciences, Janssen Research & Development, L.L.C., San Diego, CA, USA

Jacqueline Kai Chin Chuah, Institute of Bioengineering and Nanotechnology, The Nanos, Singapore

Rachel Church, University of North Carolina Institute for Drug Safety Sciences, Chapel Hill, NC, USA

Thomas J. Colatsky, Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA

Donna M. Dambach, Safety Assessment, Genentech Inc., South San Francisco, CA, USA

Mark R. Davies, QT-Informatics Limited, Macclesfield, England

Dolores Diaz, Discovery Toxicology, Safety Assessment, Genentech, Inc., South San Francisco, CA, USA

Alison Easter, Biogen Inc., Cambridge, MA, USA

Heidrun Ellinger-Ziegelbauer, Investigational Toxicology, GDD-GED-Toxicology, Bayer Pharma AG, Wuppertal, Germany

Chandikumar S. Elangbam, Pathophysiology, Safety Assessment, GlaxoSmithKline, Research Triangle Park, NC, USA

Steven K. Engle, Lilly Research Laboratories, Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA

Ellen Evans, Immunotoxicology Center of Emphasis, Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA

Craig Fisher, Drug Safety Evaluation, Takeda California Inc., San Diego, CA, USA

Jay H. Fortner, Veterinary Science & Technology, Comparative Medicine, Pfizer Inc., Groton, CT, USA

David J. Gallacher, Global Safety Pharmacology, Janssen Research & Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium

Priyanka Garg, Stanford Cardiovascular Institute, Institute for Stem Cell Biology and Regenerative Medicine, Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA, USA

Lauren M. Gauthier, Investigative Toxicology, Drug Safety Research and Development, Pfizer Inc., Andover, MA, USA

Jean-Charles Gautier, Preclinical Safety, Sanofi, Vitry-sur-Seine, France

Gary Gintant, Integrative Pharmacology, Integrated Science & Technology, Abbvie, North Chicago, IL, USA

Christopher E.P. Goldring, MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, The Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Warren E. Glaab, Systems Toxicology, Investigative Laboratory Sciences, Safety Assessment, Merck Research Laboratories, West Point, PA, USA

Brian D. Guth, Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach (Riss), Germany; DST/NWU, Preclinical drug Development Platform, Faculty of Health Sciences, North-West University, Potchefstroom, South Africa

Robert L. Hamlin, Department of Veterinary Medicine and School of Biomedical Engineering, The Ohio State University, Columbus, OH, USA

Alison H. Harrill, Department of Environmental and Occupational Health, Regulatory Sciences Program, The University of Arkansas for Medical Sciences, Little Rock, AR, USA

Dylan P. Hartley, Drug Metabolism and Pharmacokinetics, Array BioPharma Inc., Boulder, CO, USA

Patrick J. Hayden, MatTek Corporation, Ashland, MA, USA

James A. Heslop, MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, The Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Gregory Hinkle, Bioinformatics, Alnylam Pharmaceuticals Inc., Cambridge, MA, USA

Mary Jane Hinrichs, Biologics Safety Assessment, MedImmune, Gaithersburg, MD, USA

Kimberly M. Hoagland, Integrated Discovery and Safety Pharmacology, Department of Comparative Biology and Safety Sciences, Amgen Inc., Thousand Oaks, CA, USA

Daniel Holder, Biometrics Research, Merck Research Laboratories, West Point, PA, USA

Michelle J. Horner, Comparative Biology and Safety Sciences (CBSS) - Toxicology Sciences, Amgen Inc., Thousand Oaks, CA, USA

Chuchu Hu, Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration (NCTR/FDA), Jefferson, AZ, USA; Zhejiang Institute of Food and Drug Control, Hangzhou, China

Peng Huang, Institute of Bioengineering and Nanotechnology, The Nanos, Singapore

Wenhu Huang, General Toxicology, Drug Safety Research and Development, Pfizer Inc., La Jolla, CA, USA

Brandon D. Jeffy, Exploratory Toxicology, Celgene Corporation, San Diego, CA, USA

Paul Jennings, Division of Physiology, Department of Physiology and Medical Physics, Medical University of Innsbruck, Innsbruck, Austria

Raymond Kemper, Discovery and Investigative Toxicology, Drug Safety Evaluation, Vertex Pharmaceuticals, Boston, MA, USA

Helena Kandárová, MatTek In Vitro Life Science Laboratories, Bratislava, Slovak Republic

J. Gerry Kenna, Fund for the Replacement of Animals in Medical Experiments (FRAME), Nottingham, UK

Patrick Kirby, Drug Safety and Research Evaluation, Takeda Boston, Takeda Pharmaceuticals International Co., Cambridge, MA, USA

Neil R. Kitteringham, MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, The Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Mitchell Klausner, MatTek Corporation, Ashland, MA, USA

Erik Koenig, Molecular Pathology, Takeda Boston, Takeda Pharmaceuticals International Co., Cambridge, MA, USA

Yue Ning Lam, Institute of Bioengineering and Nanotechnology, The Nanos, Singapore

Lawrence H. Lash, Department of Pharmacology, School of Medicine, Wayne State University, Detroit, MI, USA

Hank Lin, Drug Safety Research and Development, Pfizer Inc., Cambridge, MA, USA

Hua Rong Lu, Global Safety Pharmacology, Janssen Research & Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium

Karen M. Lynch, Safety Assessment, GlaxoSmithKline, King of Prussia, PA, USA

Jing Ying Ma, Molecular Pathology, Discovery Sciences, Janssen Research & Development, L.L.C., San Diego, CA, USA

Jonathan M. Maher, Discovery Toxicology, Safety Assessment, Genentech, Inc., South San Francisco, CA, USA

Sherry J. Morgan, Preclinical Safety, AbbVie, Inc., North Chicago, IL, USA

J. Eric McDuffie, Mechanistic & Investigative Toxicology, Discovery Sciences, Janssen Research & Development, San Diego, CA, USA

Joseph Milano, Milano Toxicology Consulting, L.L.C., Wilmington, DE, USA

Robin Mogg, Early Clinical Development Statistics, Merck Research Laboratories, Upper Gwynedd, PA, USA

Rounak Nassirpour, Biomarkers, Drug Safety Research and Development, Pfizer Inc., Andover, MA, USA

Charlotte M.L. Nugues, MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, The Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Andrew J. Olaharski, Toxicology, Agios Pharmaceuticals, Cambridge, MA, USA

B. Kevin Park, MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, The Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Mikael Persson, Lundbeck, Valby, Denmark; Currently at AstraZeneca, Molndal, Sweden

Amy C. Porter, Predictive Safety Testing Consortium (PSTC), Critical...